Back to today’s briefing

Story perspectives

Bayer Partners with Kumquat for $1.3B Cancer Breakthrough

8/14/2025

37 3

Summary

Story summary

Bayer and Kumquat Biosciences are joining forces in a groundbreaking $1.3 billion partnership to advance Kumquat's KRAS G12D inhibitor, aimed at tackling common mutations in pancreatic, colorectal, and lung cancers. With Kumquat spearheading initial studies and Bayer overseeing later development, this collaboration not only bolsters Bayer's oncology efforts but also propels Kumquat's clinical ambitions after FDA approval.

1 of 1

Story summary

Bayer and Kumquat Biosciences are joining forces in a groundbreaking $1.3 billion partnership to advance Kumquat's KRAS G12D inhibitor, aimed at tackling common mutations in pancreatic, colorectal, and lung cancers. With Kumquat spearheading initial studies and Bayer overseeing later development, this collaboration not only bolsters Bayer's oncology efforts but also propels Kumquat's clinical ambitions after FDA approval.